SYS6043

DRUG4 trials

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd., CSPC Megalith Biopharmaceutical Co.,Ltd., Conjupro Biotherapeutics, Inc.

Conditions

Advanced Metastatic CancerAdvanced Solid TumorsAdvanced/Metastatic Solid TumorsBreast CancerCancerOvarian CancerPlatinum-resistant Fallopian Tube CancerPlatinum-resistant Ovarian Cancer

Phase 1

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors

RecruitingNCT07241936

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Advanced Solid Tumors

Start: 2025-11-13End: 2028-10-30Target: 444Updated: 2025-11-28

Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors

RecruitingNCT07415863

CSPC Megalith Biopharmaceutical Co.,Ltd.Advanced/Metastatic Solid Tumors

Start: 2024-12-30End: 2028-06-30Target: 820Updated: 2026-02-17

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

RecruitingNCT07424547

Conjupro Biotherapeutics, Inc.Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer +4

Start: 2026-03-03End: 2030-04-01Target: 386Updated: 2026-04-07

Phase 3

A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Not yet recruitingNCT07708753

CSPC Megalith Biopharmaceutical Co.,Ltd.Platinum-resistant Ovarian Cancer, Platinum-resistant Primary Peritoneal Cancer, Platinum-resistant Fallopian Tube Cancer

Start: 2026-07-01End: 2030-12-01Target: 460Updated: 2026-07-16